Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chemotherapy for recurrent cervical carcinoma.

David H Moore1

  • 1Gynecologic Oncology of Indiana, Indianapolis, Indiana 46237, USA. david.moore@ssfhs.org

Current Opinion in Oncology
|August 9, 2006
PubMed
Summary

Chemotherapy for cervical cancer shows improved outcomes with cisplatin combinations. However, survival remains poor, necessitating further research into novel treatments and targeted therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study.

Gynecologic oncology·2023
Same author

Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062).

Molecular cancer therapeutics·2020
Same author

Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).

Lancet (London, England)·2017
Same author

Surgical staging of endometrial cancer: robotic versus open technique outcomes in a contemporary single surgeon series.

Journal of robotic surgery·2016
Same author

ACR Appropriateness Criteria® Adjuvant Management of Early-Stage Endometrial Cancer.

Oncology (Williston Park, N.Y.)·2016
Same author

Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis.

Gynecologic oncology·2016

Area of Science:

  • Oncology
  • Clinical Trials
  • Cervical Cancer Treatment

Background:

  • Cervical cancer prognosis is poor when chemotherapy is the sole treatment option.
  • Recent trials show improved outcomes with specific cisplatin-based chemotherapy combinations.

Purpose of the Study:

  • To review the evolution of phase III trials in cervical cancer treatment.
  • To highlight the development of current chemotherapy standards.

Main Methods:

  • Review of phase III clinical trials in cervical cancer.
  • Analysis of chemotherapy regimens, including cisplatin combinations.

Main Results:

  • Single-agent cisplatin has limited impact on survival.
  • Cisplatin combined with paclitaxel or topotecan improved response rates and progression-free survival.
  • Cisplatin plus topotecan demonstrated improved overall survival without compromising quality of life.

Conclusions:

  • Despite advances, median survival for cervical cancer remains under one year.
  • Investigational trials for non-platinum regimens are crucial.
  • Future research should focus on emerging biological therapies.

Related Experiment Videos